文献速递前列腺癌

确认性活检依从性对前列腺癌主动监测肿瘤学结局的影响

Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
PubMed 文献 · J Urol · 2020-04-24

该研究基于1995至2018年前瞻性单臂队列中1,275例接受主动监测的前列腺癌患者,纳入1,043例随访至少3年者,按入组24个月内是否依从确认性活检分组。不依从者治疗后复发率更高(19% vs 12%,HR 1.64,95%CI 1.19-2.26,p=0.003),转移率更高(7% vs 2%,HR 3.56,95%CI 1.8-7.0,p=0.0003),但病因特异性生存无显著差异。

要点

  • 不依从确认性活检与治疗后复发风险升高相关(HR 1.64)。
  • 不依从确认性活检与转移风险升高相关(HR 3.56)。
  • 两组病因特异性生存无显著差异。

核心结论

  • 不依从确认性活检会削弱主动监测前列腺癌患者的肿瘤控制。
  • 患者和医生应认识到主动监测方案依从性的重要性。

研究设计与样本

  • 回顾性分析1995至2018年前瞻性单臂队列中接受主动监测的前列腺癌患者。
  • 共入组1,275例,其中1,043例随访至少3年并纳入分析,中位随访9.1年。
  • 按入组24个月内是否依从确认性活检进行分层。

主要发现

  • 1,043例纳入分析患者中425例接受局限性前列腺癌治疗。
  • 不依从确认性活检者治疗后复发率19% vs 12%(HR 1.64,95%CI 1.19-2.26,p=0.003)。
  • 不依从确认性活检者转移率7% vs 2%(HR 3.56,95%CI 1.8-7.0,p=0.0003)。
  • 校正年龄、前列腺特异抗原和Grade Group后结果仍显著。
  • 两组病因特异性生存无显著差异,入组时为Grade Group 1的亚组结果一致。

临床怎么用

  • 对主动监测患者应强调按方案完成确认性活检的重要性。
  • 不依从确认性活检者需警惕治疗后复发和转移风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance for prostate cancer relies on regular prostate specific antigen tests and surveillance biopsies. Compliance rates with biopsies vary but the subsequent impact on oncologic outcomes is not known. The objective of this study was to determine whether noncompliance with the confirmatory biopsy negatively impacts prostate cancer specific outcomes. MATERIALS AND METHODS: A retrospective analysis was performed on a prospective single-arm cohort of men enrolled in active surveillance for prostate cancer between 1995 and 2018 with a median followup of 9.1 years. A total of 1,275 patients were enrolled and 1,043 had a minimum of 3 years of followup and were included in the analysis. Patients were stratified by compliance with a confirmatory biopsy within 24 months of enrollment in active surveillance. The primary outcome was recurrence-free survival. Secondary outcomes included metastatic-free survival and cause specific survival. RESULTS: A total of 1,275 patients were enrolled, and 1,043 had a minimum of 3 years of followup and were included in the analysis, of whom 425 were treated for localized prostate cancer. Patients noncompliant with the confirmatory biopsy had higher rates of recurrence after treatment (19% vs 12%, HR 1.64, 95% CI 1.19-2.26, p=0.003) and metastases (7% vs 2%, HR 3.56, 95% CI 1.8-7.0, p=0.0003) even after accounting for age, prostate specific antigen and Grade Group. Cause specific survival was not significantly different between the 2 groups. The results were consistent even in the subset of patients with Grade Group 1 disease at study entry. CONCLUSIONS: Noncompliance with a confirmatory biopsy compromises the control of prostate cancer in men followed on active surveillance. Patients and physicians should be aware of the importance of adhering to protocol for men on active surveillance.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Detsky JS, Ghiam AF, Mamedov A, et al. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. J Urol. 2020. PMID: 32330406. doi:10.1097/JU.0000000000001091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。